Spero Therapeutics
SPRO
87 hedge funds and large institutions have $338M invested in Spero Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 25 reducing their positions, and 7 closing their positions.
66% more call options, than puts
Call options by funds: $2M | Put options by funds: $1.21M
39% more capital invested
Capital invested by funds: $244M → $338M (+$94.3M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 88 → 87 (-1)
1.73% less ownership
Funds ownership: 58.87% → 57.14% (-1.7%)
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$11.8M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.58M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.86M |
| 4 |
WJWM
Williams Jones Wealth Management
New York
|
+$1.69M |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$937K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$5.27M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$991K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$719K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$515K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$391K |
SPRO Hedge Fund Activity: Q3 2021 in Review
87 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2021, worth a combined $338M — up 39% from $244M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SPRO and 6 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 22 added.
The largest buyer was Aquilo Capital Management, adding an estimated $11.8M. The largest seller was BVF Inc, cutting an estimated $5.27M.
- 87 institutional investors held Spero Therapeutics (SPRO) as of Q3 2021, down from 88 in Q2 2021.
- Funds reported $338M of Spero Therapeutics stock for Q3 2021, up 39% quarter-over-quarter.
- 6 funds opened new Spero Therapeutics positions in Q3 2021 and 7 closed out, a net change of -1 holder.
- The largest Spero Therapeutics buyer in Q3 2021 was Aquilo Capital Management, an estimated $11.8M added.
- The largest Spero Therapeutics seller in Q3 2021 was BVF Inc, an estimated $5.27M sold.
Based on aggregated 13F filings for Q3 2021.